VG1177
/ VG Lifesciences
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 14, 2019
Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients
(clinicaltrialsregister.eu)
- P2; N=10; Ongoing; Sponsor: Erasmus University Medical Center
Clinical • New P2 trial
1 to 1
Of
1
Go to page
1